Increasing sales of new products and growing demand for vaccines and consumer healthcare goods helped lift GlaxoSmithKline (GSK)'s sales figures 8 percent in the first quarter to £6.2 billion ($9.1 billion), the company announced Wednesday.
The British drugmaker added that its newly launched respiratory and HIV medicines had offset falling sales of ageing lung treatment Advair.
"We think this is a strong solid quarter for the company, especially because we are seeing good, healthy performance across all three of our businesses — pharma, vaccine and consumer," outgoing chief executive Andrew Witty told CNBC on Wednesday.
However, net profit for the quarter was down 97 percent to £352 million pounds, with earnings per share at 5.8 pence. Both figures reflected the one-off boost last year from of the company's oncology disposal.